Bexxar

BEXXAR (Tositumomab and Iodine I 131 Tositumomab)

The BEXXAR therapeutic regimen (Tositumomab and Iodine I 131 Tositumomab) is indicated for the treatment of patients with CD20 antigen-expressing relapsed or refractory, low grade, follicular, or transformed non-Hodgkin's lymphoma, including patients with Rituximab-refractory non-Hodgkin's lymphoma.

IBA Molecular compounds and delivers the BEXXAR therapeutic regimen, which consists of the anti-neoplastic radioimmunotherapeutic monoclonal antibody-based regimen composed of the monoclonal antibody, Tositumomab, and the radiolabeled monoclonal antibody, Iodine I 131 Tositumomab.

For full prescribing and product information, please visit http://us.gsk.com/products/assets/us_bexxar.pdf

To discuss availability, please contact your IBA Representative.